EuropeResearch and clinical trials
In pulmonary sarcoidosis, methotrexate was not inferior to prednisone as first treatment
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
A study comparing first treatment options in pulmonary sarcoidosis has been published. A total of 138 previously untreated patients were randomly assigned to prednisone or methotrexate. After 24 weeks, the increase in lung capacity was similar in the two groups. Side effects differed: weight gain and insomnia were common with prednisone, and nausea and fatigue with methotrexate.
What does it mean for patients and families?
The result shows that there may be an alternative to cortisone as first treatment. The choice of drug is made with the doctor, taking side effects into account as well.
Source
Scientific paper: First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. The New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2501443 · PubMed 40387020
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Sarcoidosis
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.